Unknown

Dataset Information

Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity.


ABSTRACT: There is an increasing prevalence of obesity worldwide, associated with significant morbidity and mortality, which frequently reduces quality of life and life expectancy. Consequently, there is a substantial and growing personal and economic burden necessitating the development of more effective therapies for obesity. Glucagon-like peptide-1 receptor analogues (GLP-1RAs) are licensed for the treatment of type 2 diabetes (T2D), and there is substantial evidence that these drugs not only improve cardiovascular outcomes but also promote weight loss. More recent evidence supports the use of the GLP-1RAs liraglutide and semaglutide in people with obesity without T2D. This article discusses the results of the major cardiovascular outcome trials for GLP-1RAs in people with T2D, the SCALE Obesity

SUBMITTER: Williams DM 

PROVIDER: S-EPMC9354511 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature